Quick Answer
Mineralys Therapeutics, Inc. reported Total Assets of $661.81 million for the year ending 2025.
- Mineralys Therapeutics, Inc. showed an increase of +221.4% in Total Assets from 2024 to 2025.
- This data is from Mineralys Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $306.44 million | Q2 2023: $291.22 million | Q3 2023: $277.56 million | Q1 2024: $347.25 million | Q2 2024: $318.49 million | Q3 2024: $268.25 million | Q1 2025: $354.94 million | Q2 2025: $335.72 million | Q3 2025: $599.95 million.
- Over the full 4 years of available data (2022 to 2025), Mineralys Therapeutics, Inc.'s Total Assets has grown by 478.3%.
- Historical annual values: Fiscal year 2025: $661.81 million | Fiscal year 2024: $205.90 million | Fiscal year 2023: $251.64 million | Fiscal year 2022: $114.44 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: